Innovative Drug Targets Addressed in Recent Research

Extensive research is currently being conducted worldwide on pharmaceuticals targeting novel pathways. In 2024, the U.S. Food and Drug Administration (FDA) approved numerous new drugs with innovative targets, as reported by researchers from the Coriolan Dragulescu Institute of Chemistry in Timisoara, Romania.

Among these developments is Revumenib (Revuforj®), a low-molecular-weight drug that arose from an extensive search for menin inhibitors for cancer therapy. This compound inhibits the interaction between both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of KMT2A fusion proteins to menin is implicated in activating a leukemogenic transcriptional pathway in acute leukemias with KMT2A rearrangements.

Additionally, the monoclonal antibody Tarlatamab (Imdelltra®) has gained approval for the treatment of advanced small cell lung cancer. This bispecific antibody binds to DLL3 (Delta-like Ligand 3) present on the surface of tumor cells and to CD3 on cytotoxic T cells, thereby enhancing T-cell-mediated destruction of tumor cells.

Another notable development is Nogapendekin alfa inbakicept (Anktiva®), a fusion protein composed of two Nogapendekin alfa (IL-15N72D variant) units and Inbakicept (a dimeric IL-15R?-Sushi domain-IgG1-Fc domain fusion protein). This drug acts as an IL-15 receptor agonist, promoting the proliferation of natural killer cells, CD8+ T cells, and memory T cells. It is administered in conjunction with the Bacillus Calmette-Guérin (BCG) vaccine via intravesical instillation for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer.

Imetelstat (Rytelo®), an antisense oligonucleotide covalently linked to a palmitic acid moiety, binds to the RNA component of human telomerase. It inhibits the activity of telomerase reverse transcriptase (TERT), which is elevated in patients suffering from myelodysplastic syndromes.

Finally, Flurpiridaz (18F) (Flyrcado®) is a radioactive diagnostic agent produced using a cyclotron for use in positron emission tomography (PET) to assess myocardial perfusion. By targeting heart tissue with active mitochondria, it facilitates the evaluation of blood flow in the myocardium and aids in diagnosing myocardial ischemia and infarction.

The timeline for when these substances will be available in the European Union remains uncertain. However, a marketing authorization application for Nogapendekin alfa inbakicept has already been submitted to the European Medicines Agency (EMA).